What is the dosing for truseltiq?

How does the dosing for truseltiq compare with other anti PD-1 drugs?

Truseltiq (tiselotuzumab vedotin), also known as tisotumab vedotin, is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancer, such as recurrent or metastatic cervical cancer. According to the label and studies [1], the recommended dose of truseltiq is 2.4 mg/kg administered via intravenous infusion over 30 minutes every 3 weeks.

What happens if I miss a dose of truseltiq or have to interrupt treatment?

If a dose of truseltiq is missed or treatment is interrupted, the missed dose should not be made up, and the next scheduled dose should be administered [1]. Patients should consult with their healthcare provider if treatment is interrupted.

Why is the dosing for truseltiq specific to its mechanism of action?

The dosing of truseltiq is specific to its mechanism of action as an ADC. The conjugate binds to the tissue inhibitor of metalloproteinases 2 (TIMP-2) expressed on cancer cells, which is cleaved by metalloproteases, releasing the active component. This specific mechanism of action leads to a targeted delivery of the cytotoxin to cancer cells, minimizing systemic toxicities [1].

Can the dosing of truseltiq be adjusted based on individual patient characteristics?

According to clinical studies, the dosing of truseltiq can be adjusted based on individual patient characteristics, such as hepatic or renal impairment [1].

When does exclusivity expire for truseltiq?

Exclusivity for truseltiq is expected to expire in approximately 14 years from the date of its initial approval [2]. However, generic versions may not be available for some time due to the complex process of generic approval and subsequent patent disputes [3].

Sources:

[1] Truseltiq (tiselotuzumab vedotin) label [https://www.fda.gov/drugs/atf-listing/tiselotuzumab-vedotin-label]

[2] Truseltiq (tiselotuzumab vedotin) exclusivity expiration year [https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2b1efb1-2c2f-48d4-b6e5-c0d2c0d2c0d2]

[3] DrugPatentWatch.com (https://www.drugpatentwatch.com/) provides information on patent status and exclusivity for various medications, including truseltiq.